The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence of efficacy and safety in patients who did not respond to conventional or biologic therapies.
Crohn’s disease, while commonly diagnosed in adults, affects around 25% of patients during childhood or adolescence. The onset in younger individuals is linked to severe disease progression, malnutrition, and interference with critical growth periods, which can impact mental health and overall quality of life…
